Trv Gp Ii, LLC Blueprint Medicines Corp Transaction History

Trv Gp Ii, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 06, 2019	SELL	$73.54 - $97.8 $64.6 Million - $86 Million	-878,875 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$60.96 - $101.18 $96 Million - $159 Million	-1,574,878 Reduced 64.18%	878,875 $55.8 Million
Q4 2017 Feb 13, 2018	BUY	$62.91 - $88.32 $154 Million - $217 Million	2,453,753	2,453,753 $185 Million

340

62M

987K

578K

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.26B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Trv Gp Ii, LLC, based on Form 13F filings with the SEC.

Stay updated on Trv Gp Ii, LLC with notifications on news.